Investors & Media

Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study

– Positive data from a Phase 2 study of IONIS-FB-L Rx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif. , July 11, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and

Read more
You are now leaving https://www.ionispharma.com to visit